<DOC>
	<DOCNO>NCT02702323</DOCNO>
	<brief_summary>This study mainly evaluate clinical effect Apatinib treatment patient pulmonary metastasis hepatocellular carcinoma.Half participant receive Apatinib transcatheter arterial chemoembolization ( TACE ) therapy combination , half receive TACE therapy alone .</brief_summary>
	<brief_title>Treatment Patients With Pulmonary Metastasis Liver Cancer With Apatinib Combination With TACE : Clinical Study</brief_title>
	<detailed_description>Apatinib VEGFR target tyrosine kinase inhibitor , preliminary demonstrate efficacy safety treatment advance hepatocellular carcinoma phase II stage research . Pulmonary metastasis hepatocellular cancer one difficulties clinical practice , 's sensitive systemic chemotherapy.This phase Ⅲ study aim evaluate efficacy safety Apatinib treatment advance hepatocellular cancer pulmonary metastasis .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>clinical diagnosis hepatocellular carcinoma refuse sorafenib treatment least one measurable pulmonary lesion expect survival time ≥ 12 week within four week study receive radiotherapy chemotherapy With variety factor influence oral drug take absorption ( unable swallow , chronic diarrhea intestinal obstruction )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>pulmonary metastasis</keyword>
	<keyword>Apatinib</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>